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Introduction
The clinical diagnosis of diabetes, reflected by hyperglycemia, is 
straightforward; however, identifying the underlying molecular 
mechanism(s) is often challenging and sometimes not possible. 
These challenges are further confounded by well-documented 
heterogeneity of type 2 diabetes and with heterogeneity of type 
1 diabetes (T1D) increasingly being recognized (1, 2). Partly, 
this is because the molecular defect(s) for most forms of diabe-
tes is not known and partly because the molecular phenotyping 
of tissues involved in human diabetes is inadequate and limited. 
Critical human tissue and cellular samples relevant to diabetes 
are challenging to collect, sometimes not accessible, or limited 
by tissue processing that precludes functional analysis and the 
application of new technologies. For example, technical barriers 
prevent sampling of the human pancreas, as it cannot be safely 
and routinely biopsied in living individuals and rapidly undergoes 
autodigestion postmortem, hindering adequate molecular diag-
nostic and clinical phenotyping of the human pancreatic islet in 
all forms of diabetes.
To overcome such limitations, experimental models have 
been used to discover critical contributions to our understand-
ing of human physiology and disease. However, in several 
instances, widely used model systems appear limited in their 
translation into clinically relevant information and may even 
inadvertently be misleading. For example, gene expression 
responses to inflammation in mice appear to have incomplete 
predictive clinical value and correlate with only a minority of 
human gene expression changes (3). Similarly, some rodent 
models of human monogenic diabetes do not fully reflect the 
altered glucose homeostasis observed in humans. For example, 
heterozygous mutations in the key pancreatic islet transcription 
factor hepatocyte nuclear factor-1α (HNF1A), which causes the 
most common form of monogenic diabetes, does not mimic the 
human disease in mouse models, leaving the pathophysiologic 
effect of HNF1A genetic variants on the human pancreatic islet 
incompletely understood (4–6).
To overcome these translational barriers and improve pre-
clinical modeling of human disease, renewed emphasis and new 
approaches to study human tissue have led to the development 
of collaborative human tissue repositories or accessible databas-
es such as the Network of Pancreatic Organ donors with Diabetes 
(nPOD), the Genotype Tissue Expression Project (GTEX), and the 
Human Islet Research Network (HIRN). Studies of human pancre-
atic islets have illustrated important similarities and differences 
from rodent islets in endocrine cell composition and arrangement, 
innervation, vasculature, and function (7–9).
Using infrastructure to study pancreatic islets and tissue from 
donors with diabetes in conjunction with the donors’ deidentified 
medical records, investigators are working to better understand 
the changes in the pancreatic islet in diabetes (10–12). In this 
report, we describe unexpected functional and molecular find-
ings from the pancreas of an individual with the clinical diagnosis 
Using an integrated approach to characterize the pancreatic tissue and isolated islets from a 33-year-old with 17 years of 
type 1 diabetes (T1D), we found that donor islets contained β cells without insulitis and lacked glucose-stimulated insulin 
secretion despite a normal insulin response to cAMP-evoked stimulation. With these unexpected findings for T1D, we 
sequenced the donor DNA and found a pathogenic heterozygous variant in the gene encoding hepatocyte nuclear factor-
1α (HNF1A). In one of the first studies of human pancreatic islets with a disease-causing HNF1A variant associated with 
the most common form of monogenic diabetes, we found that HNF1A dysfunction leads to insulin-insufficient diabetes 
reminiscent of T1D by impacting the regulatory processes critical for glucose-stimulated insulin secretion and suggest a 
rationale for a therapeutic alternative to current treatment.
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responded normally to high glucose coupled with the phosphodies-
terase inhibitor, isobutylmethylxanthine (IBMX). Moreover, gluca-
gon secretion from donor islet α cells had an abrogated response to 
potent α cell stimuli such as low glucose (1.7 mM) and epinephrine 
(1 μM) and, strikingly, showed an inhibitory response to membrane 
depolarization by KCl (Supplemental Figure 1, E, F, and H). Donor 
pancreas islet innervation and vasculature, important for coordinat-
ed islet function in vivo (8, 14), were normal (Supplemental Figure 1I). 
Because of these unexpected histological and functional findings, we 
sequenced the donor DNA for variants associated with monogenic 
diabetes and uncovered a heterozygous, disease-associated variant 
in a conserved region of the POUH DNA binding domain of HNF1A 
(c.779C>T, p.Thr260Met) (15) (Supplemental Table 2 and Supple-
mental Figure 1J). Variants in HNF1A comprise the most common 
form of maturity-onset diabetes of the young 3 (termed MODY3) (16).
HNF1AT260M displayed compromised DNA binding. Nuclear 
HNF1A protein was detected in both the exocrine and endocrine 
compartments of the donor pancreas, with normal expression in 
β cells and α cells (Figure 2A and Supplemental Figure 2, A and 
B). The DNA binding capacity of the altered HNF1AT260M protein, 
as assessed by electrophoretic mobility shift assay (EMSA), was 
severely compromised compared with HNF1AWT protein (Figure 
2B and Supplemental Figure 2, C–E). Accordingly, HNF1AT260M 
had little to no ability to stimulate MAFA region 3 enhancer-driv-
of T1D, thus highlighting how systematic analysis of rare human 
samples can provide critical insight into human disease and poten-
tially lead to new approaches to therapy.
Results and Discussion
As part of studies of the pancreas and islets from individuals with 
T1D (10–12), we were surprised to find that analysis of sections 
from the head, body, and tail regions of one donor’s pancreas 
showed that all islets contained insulin-positive β cells (Figure 1A 
and Supplemental Figure 1A and insets, and Supplemental Tables 
1, 3, and 4; supplemental material available online with this article; 
https://doi.org/10.1172/JCI121994DS1), but lacked insulitis typi-
cal of T1D (infiltration of CD45+ cells) (13).
Donor pancreas had normal β cell mass, but β cells were functionally 
impaired. The donor pancreas had β and δ cell mass within the normal 
range, with slightly elevated α cell mass (Figure 1B and Supplemental 
Figure 1B) and an increased α/β cell ratio (Supplemental Figure 1, C, 
G, and H). No β cell apoptosis (TUNEL) or proliferation (Ki67) was 
detected (Supplemental Figure 1D). In a dynamic perifusion system, 
isolated donor islets had normal insulin content but had higher basal 
insulin secretion, lacked biphasic glucose-stimulated insulin secre-
tion (GSIS), and had a decreased secretory response to KCl-medi-
ated membrane depolarization (Figure 1C and inset, Figure 1D, and 
Supplemental Figure 1G). Despite the lack of GSIS, the donor’s islets 
Figure 1. Histological and functional analysis of HNF1A+/T260M pancreas and islets. (A) Example of expression of insulin (INS), glucagon (GCG), and 
somatostatin (SOM) in donor’s native pancreatic tissue compared with control. Scale bar: 50 μm. (B) β and α cell mass (grams) in HNF1A+/T260M pancreas 
compared with controls (n = 7 donors; ages 10–55 years). Each data point represents the average mass across the combined pancreatic head, body, and tail 
regions. (C) Insulin secretion in islets isolated from the HNF1A+/T260M pancreas compared with controls (n = 6 donors; ages 8–55 years) and normalized to 
overall islet cell volume (expressed as islet equivalents, IEQs). Islets were teated with 5.6 mM glucose (G 5.6); 16.7 mM glucose (G 16.7); 16.7 mM glucose 
plus 100 μM isobutylmethylxanthine (G 16.7 + IBMX 100); 1.7 mM glucose plus 1 μM epinephrine (G 1.7 + Epi 1); or 20 mM potassium chloride (KCl 20) at the 
indicated times. Insets show average insulin response of controls and HNF1A+/T260M donor to 30-minute stimulation with 16.7 mM glucose. (D) Integrated 
insulin secretion was calculated as the area under the curve (AUC) for the indicated secretagogue (shaded to correspond to color-matched regions of peri-
fusion trace in panel C). Results of control samples are expressed as mean ± SEM.
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ulatory networks required for β cell function rather than main-
taining identity. Decreased expression of known (e.g., MLXIPL, 
HNF4A, PKM, OGDH, PPP1R1A, G6PC2, and TMEM27) (21) and 
previously undescribed HNF1A targets (IAPP, ABCC8, KCNJ11, 
TMEM37, SYNGR4, and FOXRED2) likely contributes to the loss 
of GSIS identified by islet perifusion (Figure 3C). Notably, most 
voltage-gated calcium channels, such as L-type and P/Q-type, 
were not changed in HNF1A+/T260M β cells, but ATP-sensitive chan-
nels were decreased (ABCC8, KCNJ11, KCNJ8, and FXYD2). Path-
way analysis of HNF1A+/T260M β cells revealed changes in glucose 
metabolism and ATP production important in glucose-mediated 
insulin secretory processes as well as in core cellular pathways such 
as gene transcription, intracellular protein transport (i.e., synthe-
sis, ubiquitination, and exocytosis), cell stress response, and cell 
signaling (Figure 3D and Supplemental Tables 5 and 7). Approxi-
mately 50% of the genes differentially expressed in HNF1A+/T260M 
β cells were also altered in donor α cells (Supplemental Figure 3, 
A–G), suggesting that HNF1A dysfunction is a common effector in 
both cell types (Supplemental Tables 5–7). We also noted that oth-
er processes such as amino acid nutrient sensing and metabolism, 
cell cycle regulators, and cell adhesion/motility were altered in 
HNF1A+/T260M islet cells (SLC38A4, GLUL, IGFBP5, and CREB3L1).
en reporter activity relative to HNF1AWT in cotransfection assays 
(Supplemental Figure 2, F and G). Notably, each of these proteins 
was expressed at similar levels, and WT activation was dependent 
on HNF1A-site binding, as described previously (17). Furthermore, 
HNF1AT260M decreased HNF1AWT activation in a dose- dependent 
manner, providing evidence that the dominant-negative action 
of HNF1AT260M is due to dimerization with HNF1AWT (Supple-
mental Figure 2, F and G). Moreover, protein modeling predicted 
that disrupted DNA binding results from the missing hydrogen 
donor at position 260 in the variant protein, which destabilizes the 
DNA-binding Arg-263 residue (Figure 2C), yet leaves the distinct 
dimerization domain in the transcription factor intact (18).
HNF1A+/T260M β cells have preserved markers of β cell identity, but 
changes in processes critical for GSIS. RNA-sequencing and tran-
scriptional profiling of purified HNF1A+/T260M β cells (Figure 3, A 
and B) showed relatively preserved expression of INS mRNA and 
transcription factor markers of β cell identity (PDX1, NKX2.2, 
and NKX6.1), which was confirmed by protein expression analy-
sis (Supplemental Figure 2H). However, decreased expression of 
other transcription factors associated with mature β cell function 
(i.e., MAFA, SIX3, and RFX6; refs. 17, 19, and 20, respectively) 
suggests that the HNF1AT260M variant impacts transcriptional reg-
Figure 2. Expression and functional characterization of HNF1AT260M variant. (A) Analysis of donor’s native pancreatic tissue for HNF1A compared with 
controls (n = 4 donors; ages 10–55 years) revealed HNF1A protein in donor β cells. Scale bar: 50 μm. (B) Electrophoretic mobility shift assay (EMSA) shows 
that the HNF1AT260M variant has impaired DNA binding, with loss of the HNF1A-specific DNA binding complex (arrow) in Myc-tagged HNF1AT260M–trans-
fected HeLa cells compared with Myc-tagged HNF1AWT. Specificity of this complex (arrow) was shown by exclusive elimination of these species by adding 
either Myc antibody (Myc-Ab) or unlabeled oligonucleotide (WT Oligo) containing the HNF1A consensus recognition motif, but not a mutated form of this 
oligonucleotide (Comp Oligo). Moreover, HNF1A antibody (HNF1A-Ab) only supershifted (s.s.) this complex. All samples in B include oligonucleotide labeled 
with 32P as described in the supplemental material. Asterisk indicates nonspecific complexes. NT, nontransfected HeLa cells. One representative experi-
ment of 3 is shown. (C) Molecular modeling of the HNF1AT260 variant in PyMOL predicts that the hydroxyl group (red) on threonine 260 (Thr-260) stabilizes 
arginine 263 (Arg-263) by hydrogen bonding to nitrogen (blue). Arg-263 H-bonds to the DNA backbone of the fifth adenosine of the HNF1A consensus 
recognition motif (5′-CTTGGTTAATAATTCACCAGA-3′) in control conditions (18). A missense mutation from threonine to methionine at position 260 is pre-
dicted to result in the loss of this interaction by destabilizing Arg-263 and subsequently DNA binding. Results of control samples are expressed as mean ± 
SEM. See complete unedited blots in the supplemental material.
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changes in core metabolic functions, such as gene transcription, pro-
tein synthesis and degradation, unfolded protein response, and intra-
cellular and cell-cell communications in HNF1A+/T260M β cells. From 
this data set, we propose that this class of loss-of-function variants in 
HNF1A leads to insulin-insufficient diabetes, not by significant loss of 
β cell mass, but rather by impacting β cell transcriptional regulatory 
networks (HNF4A, MAFA, RFX6, SIX3, FOXA2, and MLXIPL) that 
results in impairment of β cell pathways necessary for a normal insulin 
response to glucose (Figure 4).
Furthermore, by investigating hormone secretion in isolated 
pancreatic islets, we discovered that depolarization by KCl, which 
directly stimulates hormone secretion by activating voltage-depen-
dent calcium channels, was impaired in HNF1A+/T260M α and β cells, 
in contrast to results from mouse models (4). Interestingly, elevated 
basal insulin secretion was observed in islets from this donor, con-
sistent with decreased expression of genes associated with glucose 
sensitivity of insulin secretion (G6PC2 and SLC37A4) (24). Our 
data also revealed a previously unrecognized role for HNF1A in α 
cell function, as HNF1A+/T260M impacted expression of many shared 
genes involved in hormone-regulated secretion (Supplemental Fig-
ure 3C). Transcriptomic analysis also uncovered HNF1A-regulated 
gene targets in β cells, such as PPP1R1A and RFX6, and pathways, 
like protein synthesis and amino acid metabolism. In addition, a 
This report highlights how molecular and functional findings 
in unique human samples, even in a single case, can contribute to 
our understanding of physiology and disease pathogenesis. Levels 
of HNF1A gene transcript in the human pancreas are substantial-
ly lower compared with mouse (22), such that mouse models of 
heterozygous HNF1A do not phenocopy the human disease (4–6). 
Missense mutations in the HNF1A dimerization and DNA binding 
domains account for the majority of described pathogenic HNF1A 
variants (23). Our modeling predicted that the T260M change 
would impair DNA binding of HNF1A, rendering this transcrip-
tional factor nonfunctional, which was demonstrated by EMSA 
analysis. The dose-dependent decrease in transcriptional activity 
in WT HNF1A–dependent MAFA gene activation by HNF1AT260M 
suggests that the dimerization between these proteins leads to 
impaired DNA binding activity and reduced HNF1A target gene 
expression in individuals carrying this variant.
In one of the first direct studies of human islets from an individual 
with a heterozygous, missense variant in the HNF1A locus, we show 
that this HNF1A+/T260M donor had relatively normal β cell mass and 
maintained many key markers of β cell identity but lacked an insulin 
secretory response to glucose challenge. This insulin secretory deficit 
was accompanied by alterations in genes encoding pathways of glu-
cose metabolism and ATP production, which were also coupled with 
Figure 3. Transcriptomic analysis of HNF1A+/T260M β cells. (A) Principal component analysis (PCA) plot depicts clustering of control β cells (n = 5 donors; 
ages 26–55 years) (31) separate from HNF1A+/T260M β cells. (B) The volcano plot demonstrates transcripts differentially expressed between control and 
HNF1A+/T260M β cells (red, upregulated gene expression; green, downregulated gene expression). Differential expression was calculated based on fold change 
(FC) ≥1.5 with a P-value cutoff of <0.05 for calculated Z score. (C) Genes of interest and HNF1A targets are significantly downregulated in HNF1A+/T260M β 
cells. The vertical dotted line represents FC = 1.5 times the threshold; P < 0.05 for all values shown. (D) Significant processes identified by Gene Ontology 
(GO) term-enrichment analysis are grouped and displayed by their P value on a log2 scale.
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significant family history of insulin-deficient diabetes, and/
or a low renal threshold for glucose should prompt genet-
ic testing for HNF1A variants and other monogenic forms 
of diabetes. Because of this, in collaboration with the Van-
derbilt Institutional Review Board (IRB), we are working 
to communicate our findings to the deidentified donor’s 
family and recommend diagnostic MODY genetic testing 
in potentially affected family members. Overall, this report 
shows how integrating clinical information with molecular 
and cellular analyses identified what appeared to be T1D 
was in fact part of a broader spectrum of insulin-deficient 
diabetes and provides translational insight into an incom-
pletely understood form of human diabetes.
Methods
Detailed methods are in the supplemental materials.
RNA-sequencing data were deposited in the NCBI’s 
Gene Expression Omnibus (GEO) database: GSE106148 
(control α cells), GSE116559 (control β cells), and GSE120299 
(HNF1A+/T260M donor α and β cells).
Statistics. Values are shown as mean ± standard error of 
the mean (SEM) for control samples. Data from a sample size 
of n = 1 for the donor precluded formal statistical analysis.
Study approval. The Vanderbilt University IRB declared 
that studies on deidentified human pancreatic specimens do 
not qualify as human subject research.
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